Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luis Paz-Ares

Showing results (1-10 of 407) with videos related to

Pageof 41
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 30, 2021
Response to: Bintrafusp Alfa in Second-Line Treatment of Patients With NSCLCLuis Paz-Ares
The Lancet. Oncology|January 27, 2012
Beyond first-line NSCLC therapy: chemotherapy or erlotinib?Luis Paz-Ares
British Journal of Cancer|December 9, 2020
Summary of 'The current status and future perspectives on the management of stage III NSCLC: a focus on unresectable cancer treatment paradigms'Luis Paz-Ares,
British Journal of Cancer|December 9, 2020
Foreword to 'The current status and future perspectives on the management of stage III NSCLC: a focus on unresectable cancer treatment paradigms'Luis Paz-Ares,
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2022
Extensive-Stage Small-Cell Lung Cancer: First-Line and Second-Line Treatment OptionsJon Zugazagoitia, Luis Paz-Ares
Seminars in Oncology|May 13, 2015
Immunologic checkpoint blockade in lung cancerMartin Reck, Luis Paz-Ares
European Journal of Cancer (Oxford, England : 1990)|April 2, 2013
The PARAMOUNT study and the re-challenge chemotherapy issue in advanced non-small cell lung cancerCesare Gridelli, Luis Paz-Ares
Current Molecular Pharmacology|March 23, 2010
Between bench and bed side: PI3K inhibitorsLuis Paz-Ares, Amancio Carnero
Lancet (London, England)|March 1, 2014
Treatment for early-stage lung cancer: what next?Luis Paz-Ares, Jesus Corral
JAMA Oncology|December 15, 2022
Emerging Strategies for the Treatment of Small Cell Lung Cancer: A ReviewW Jeffrey Petty, Luis Paz-Ares
Pageof 41

Showing results (1-10 of 407) with videos related to

Sort By:
Pageof 41
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 30, 2021
Response to: Bintrafusp Alfa in Second-Line Treatment of Patients With NSCLCLuis Paz-Ares
The Lancet. Oncology|January 27, 2012
Beyond first-line NSCLC therapy: chemotherapy or erlotinib?Luis Paz-Ares
British Journal of Cancer|December 9, 2020
Summary of 'The current status and future perspectives on the management of stage III NSCLC: a focus on unresectable cancer treatment paradigms'Luis Paz-Ares,
British Journal of Cancer|December 9, 2020
Foreword to 'The current status and future perspectives on the management of stage III NSCLC: a focus on unresectable cancer treatment paradigms'Luis Paz-Ares,
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2022
Extensive-Stage Small-Cell Lung Cancer: First-Line and Second-Line Treatment OptionsJon Zugazagoitia, Luis Paz-Ares
Seminars in Oncology|May 13, 2015
Immunologic checkpoint blockade in lung cancerMartin Reck, Luis Paz-Ares
European Journal of Cancer (Oxford, England : 1990)|April 2, 2013
The PARAMOUNT study and the re-challenge chemotherapy issue in advanced non-small cell lung cancerCesare Gridelli, Luis Paz-Ares
Current Molecular Pharmacology|March 23, 2010
Between bench and bed side: PI3K inhibitorsLuis Paz-Ares, Amancio Carnero
Lancet (London, England)|March 1, 2014
Treatment for early-stage lung cancer: what next?Luis Paz-Ares, Jesus Corral
JAMA Oncology|December 15, 2022
Emerging Strategies for the Treatment of Small Cell Lung Cancer: A ReviewW Jeffrey Petty, Luis Paz-Ares
Pageof 41